Cargando…
100. Safety Analysis of Live-Attenuated Measles, Mumps, Rubella Vaccine Among Hematopoietic Cell Transplant Recipients Vaccinated Within Two Years of Transplant
BACKGROUND: Measles, mumps and rubella (MMR) vaccine is a live-attenuated vaccine usually contraindicated within the first two years of hematopoietic cell transplant (HCT). During the 2019 measles outbreak at our center, the benefits of administering MMR vaccine within the first two years after HCT...
Autores principales: | Mitre, Xhoi, Feeley, Monica, Sherman, Amy C, Walsh, Stephen R, Cheng, Matthew, Kanjilal, Sanjat, Ho, Vincent T, Baden, Lindsey R, Issa, Nicolas C, Desjardins, Michaël |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644540/ http://dx.doi.org/10.1093/ofid/ofab466.100 |
Ejemplares similares
-
Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant
por: Desjardins, Michaël, et al.
Publicado: (2021) -
Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation
por: Randi, Bruno Azevedo, et al.
Publicado: (2023) -
Difficulties in Eliminating Measles and Controlling Rubella and Mumps: A Cross-Sectional Study of a First Measles and Rubella Vaccination and a Second Measles, Mumps, and Rubella Vaccination
por: Wang, Zhifang, et al.
Publicado: (2014) -
1548. Risk of Severe Herpes Zoster (HZ) in Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
por: Baumrin, Emily, et al.
Publicado: (2018) -
2467. Timeliness of Childhood Vaccination With the Combination Measles–Mumps–Rubella–Varicella Vaccine vs. the Separate Measles–Mumps–Rubella and Varicella Vaccines in the United States
por: Wolfson, Lara, et al.
Publicado: (2018)